Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH)
26.37
-1.46 (-5.25%)
NASDAQ · Last Trade: Nov 13th, 11:11 PM EST
Detailed Quote
Previous Close
27.83
Open
27.66
Bid
25.11
Ask
26.37
Day's Range
26.00 - 27.86
52 Week Range
20.39 - 47.99
Volume
488,815
Market Cap
1.27B
PE Ratio (TTM)
11.67
EPS (TTM)
2.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
451,846
Chart
About Amphastar Pharmaceuticals, Inc. - Common Stock (AMPH)
Amphastar Pharmaceuticals is a specialty pharmaceutical company that focuses on developing, manufacturing, and marketing injectable and inhalation products. The company is dedicated to providing high-quality medicines, particularly in the areas of complex generics and niche products, which include both branded and generic formulations. Amphastar's research and development efforts are geared towards addressing unmet medical needs and improving patient outcomes, with a strong emphasis on innovative therapies and cost-effective solutions in various therapeutic areas. Through its commitment to quality and regulatory standards, Amphastar aims to deliver safe and effective pharmaceuticals to healthcare providers and patients around the world. Read More
Amphastar Pharmaceuticals' third quarter results for 2025 came in ahead of Wall Street's revenue and profit expectations, despite essentially flat sales compared to the prior year. The quarter was shaped by strong performances from proprietary products BAQSIMI and Primatene MIST, both of which saw double-digit sales growth. Management attributed this momentum to enhanced commercial execution and expanded marketing partnerships. At the same time, the company faced pronounced margin pressure, primarily due to a sales mix shift, pricing declines, and increased competition in legacy products. CFO William Peters pointed to higher operating costs and a litigation provision that weighed on profitability, noting, “cost control measures were implemented to mitigate the impact of pricing pressures.”
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Viatris (NASDAQ:VTRS) and its peers.
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH)
jumped 3.9% in the afternoon session after the stock's positive momentum continued as the company reported impressive financial results for the third quarter of 2025, showing resilient performance and robust sales growth. In its earnings report from the previous day, the company disclosed net revenues of $191.8 million for the quarter. Furthermore, its adjusted net income reached $44.7 million, which translated to $0.93 per diluted share. This performance underscored the company's strong financial health, even as it navigated challenges like increased competition and sales declines in certain product areas. The positive results appeared to give investors confidence in the company's standing.
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Wednesday, November 19th, 2025, at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH)
jumped 10.9% in the afternoon session after the stock's positive momentum continued as the company reported third-quarter financial results that surpassed analyst expectations. Amphastar posted revenue of $191.8 million and adjusted earnings of $0.93 per share, beating Wall Street's consensus estimates. The strong performance was reportedly driven by robust sales of its products Baqsimi and Primatene Mist. Following the results, analyst firm Needham maintained its 'Buy' rating on the company's stock but lowered its price target to $34 from $36.
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported Q3 CY2025 results topping the market’s revenue expectations, but sales were flat year on year at $191.8 million. Its non-GAAP profit of $0.93 per share was 12.7% above analysts’ consensus estimates.
Shares of pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH)
jumped 4.9% in the afternoon session after the company reported third-quarter 2025 financial results that surpassed analyst expectations.
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales were flat year on year at $191.8 million. Its non-GAAP profit of $0.93 per share was 12.7% above analysts’ consensus estimates.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
RANCHO CUCAMONGA, CA / ACCESS Newswire / October 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2025 ended September 30, 2025, after the market closes on Thursday, November 6, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.
Since April 2025, Amphastar Pharmaceuticals has been in a holding pattern, floating around $24.52. The stock also fell short of the S&P 500’s 22.9% gain during that period.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges.
However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Amphastar Pharmaceuticals appears undervalued with a low P/E ratio, strong profitability, and solid financial health, fitting value investing criteria.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Amphastar Pharmaceuticals (AMPH) is a value stock with strong profitability, a low P/E ratio, and solid financial health, trading below intrinsic value.
